Scale-up and scale-out: what do we really need and how will we get there?

Cell & Gene Therapy Insights 2021; 7(8), 1131–1132


Published: 15 October 2021
Jan Thirkettle

Jan Thirkettle is Chief Executive Officer of Transine Therapeutics, UK based biotech developing SINEUPs (a novel lncRNA platform which upregulates protein expression) in ocular and neurodegenerative diseases. He was previously Chief Development Officer at Freeline, a clinical phase AAV gene therapy company with a novel AAV capsid platform. Jan has extensive experience in the devel¬opment and commercialisation of novel platforms including NCEs, natural products, biologics and gene therapies, and has played a role in launching products in all these classes. Prior to joining Freeline Jan led the establishment of GSK’s Cell and Gene Therapy platform and was responsible for CMC/sup¬ply for Strimvelis, the first ex vivo gene therapy to receive an EU Marketing Authorisation Application. Jan holds an MA in Chemistry and a PhD in Biological Chemistry from Oxford University.